NEW YORK, NY / ACCESS Newswire / July 28, 2025 / If you suffered a loss on your PepGen Inc. (NASDAQ:PEPG) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pepgen-inc-lawsuit-submission-form?prid=158442&wire=1&utm_campaign=22 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call […]

NEW YORK, NY / ACCESS Newswire / July 28, 2025 / Pomerantz LLP is investigating claims on behalf of investors of NWTN Inc.("NWTN" or the "Company") (NASDAQ:NWTN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether NWTN and certain of its officers and/or directors have engaged

NEW YORK CITY, NY / ACCESS Newswire / July 28, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Zeo Energy Corp. ("Zeo" or the "Company") (NASDAQ:ZEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Zeo and certain of its officers and/or

NEW YORK CITY, NY / ACCESS Newswire / July 28, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Groupon, Inc. ("Groupon" or the "Company") (NASDAQ:GRPN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Groupon and certain of its officers and/or directors

NEW YORK CITY, NY / ACCESS Newswire / July 28, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ:ALT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Altimmune and certain of its officers and/or directors

NEW YORK CITY, NY / ACCESS Newswire / July 28, 2025 / Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ:ARGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether argenx and certain of its officers and/or directors

NEW YORK, NY / ACCESS Newswire / July 28, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Abacus Global Management, Inc. ("Abacus" or the "Company") (NASDAQ:ABL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Abacus and certain of its officers and/or

NEW YORK CITY, NY / ACCESS Newswire / July 28, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against RxSight, Inc. ("RxSight" or the "Company") (NASDAQ:RXST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged

NEW YORK CITY, NY / ACCESS Newswire / July 28, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ:RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Ultragenyx and certain of its officers and/or

NEW YORK CITY, NY / ACCESS Newswire / July 28, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Capricor and certain of its officers and/or